AbbVie Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | $13.34B | $15.10B | $14.46B |
| Cost of Revenue | $4.29B | $4.22B | $4.55B | $5.30B | $4.35B | $4.00B | $4.40B | $4.21B |
| Gross Profit | $12.70B | $10.78B | $12.07B | $10.47B | $11.08B | $9.34B | $10.71B | $10.25B |
| Gross Margin | 74.7% | 71.9% | 72.6% | 66.4% | 71.8% | 70.0% | 70.9% | 70.9% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $3.63B | $3.58B | $3.90B | $3.57B | $3.25B | $3.29B | $3.86B | $4.21B |
| Operating Income | $6.43B | $3.99B | $4.54B | $1.90B | $4.89B | $3.73B | $-1.49B | $3.83B |
| Operating Margin | 37.9% | 26.6% | 27.3% | 12.1% | 31.7% | 28.0% | -9.9% | 26.5% |
| Interest Expense | $746.0M | $717.0M | $714.0M | $739.0M | $740.0M | $700.0M | $702.0M | $720.0M |
| Pretax Income | $4.28B | $1.04B | $2.67B | $714.0M | $1.55B | $1.66B | $-2.27B | $2.08B |
| Income Tax Expense | $662.0M | $342.0M | $853.0M | $526.0M | $613.0M | $372.0M | $-2.25B | $520.0M |
| Net Income | $3.61B | $695.0M | $1.82B | $186.0M | $938.0M | $1.29B | $-22.0M | $1.56B |
| Net Margin | 21.3% | 4.6% | 10.9% | 1.2% | 6.1% | 9.6% | -0.1% | 10.8% |
| EPS (Basic) | $2.04 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.02 | $0.88 |
| EPS (Diluted) | $2.03 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.02 | $0.88 |
| Shares Outstanding (Basic) | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
| Shares Outstanding (Diluted) | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
| Dividends Per Share | $1.73 | $1.73 | $1.73 | $1.64 | $1.64 | $1.64 | $1.64 | $1.55 |